Mac Profile picture
Mar 28, 2023 6 tweets 1 min read Read on X
$MDXH thread here on advantages . MDxHealth is a biotechnology company that specializes in developing and commercializing molecular diagnostic tests that aid in the diagnosis and treatment of urologic cancers. Advantages include: 1/6
1. Accurate and Early Detection: $MDXH diagnostic tests can detect cancer at an early stage, even before symptoms appear. This allows for earlier intervention and treatment, which can improve patient outcomes. 2/6
2. Personalized Treatment: $MDXH MDxHealth's tests provide information about the specific characteristics of a patient's tumor, allowing doctors to personalize treatment plans and select the most effective therapies. 3/6
3. Non-invasive: MDxHealth's diagnostic tests are non-invasive and require only a urine or blood sample, making them less painful and less invasive than traditional diagnostic methods. 4. Cost-effective: $MDXH tests are cost-effective, as they can reduce the need for more 4/6
expensive diagnostic procedures and improve patient outcomes, ultimately reducing healthcare costs. 5. Innovation: MDxHealth is constantly innovating & developing new diagnostic tests, which can improve the accuracy and effectiveness of cancer detection and treatment. 5/6 $MDXH
Overall, MDxHealth's molecular diagnostic tests offer a number of advantages for both patients and healthcare providers, including earlier detection, personalized treatment, non-invasive testing, cost-effectiveness, and ongoing innovation. $MDXH

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Mac

Mac Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @MACDcurlingup

Feb 12, 2024
Few highlights from February’s $CLRB presentation deck: Market size: There are approximately 26,000 patients with Waldenstrom's macroglobulinemia (WM) in the U.S., with 81% of patients under care in the last year currently receiving active treatment. 1/
Unmet need: There are no approved treatments for relapsed or refractory WM, and 4-12% of patients have major response rates (MRR) to treatment beyond 2nd line therapy.
Patient journey: Approximately 50% of patients are diagnosed in the 2/ $CLRB
academic setting and 55% in the community setting. About 80% of patients will receive 3rd line treatment, and 0% of patients achieve complete response (CR) with single-agent Bruton's tyrosine kinase (BTK) inhibitor therapy.
Market opportunity: There is a significant 3/ $CLRB
Read 9 tweets
Feb 9, 2024
$MCRB Seres is making significant changes to its business in order to focus on commercializing VOWST and achieving long-term sustainability. Over the past two months they have focused on the following: Workforce: reduced its workforce by 41%, or approximately 1/6
1,160 positions, across the organization. R&D: The company significantly scaled back all non-partnered research & development programs & activities, except for the completion of the SER-155 Phase 1b study. VOWST Manufacturing: Seres closed one of their donor facilities 2/6 $MCRB
and is continuing to identify additional manufacturing efficiencies. G&A : The company reduced general & administrative (G&A) expenses and is consolidating office space, including planned subleasing. Non-essential operating expenses: eliminated $MCRB 3/6
Read 6 tweets
Mar 20, 2023
Advantages $XFOR : 1.Focus on Rare Diseases: pipeline primarily focused on developing therapies for rare diseases, often lack effective treatment options. By targeting these diseases, company has the potential to bring life-changing therapies to patients who need them most 1/4
2. Innovative Drug Candidates: pipeline includes several, including Mavorixafor, which targets the CXCR4 receptor, a promising target for cancer therapy. X4P-003, a novel small molecule inhibitor NLRP3 inflammasome, potential to treat several rare diseases. $XFOR 2/4
Diversified Pipeline: $XFOR pipeline, drug candidates in different stages of development targeting different diseases, providing the company with a diversified portfolio. This diversification reduces the risk associated with any single product candidate failing. $XFOR 3/4
Read 4 tweets
Nov 14, 2021
$LPTX oncology development DKN-01, an anti-DKK1 antibody. Currently sits at $215m market cap w/ $125m in cash. Recent compelling data at ESMO from the DisTinGuish Study of DKN-01 plus tislelizumab & chemotherapy in gastric cancer patients. 1L/2L Data expected Q1 2022 1/4
DisTinGuish an open-label Phase 2 had results for 22 patients who completed treatment. 15 patients achieved (PR), (ORR) of 68.2%, 6 patients experienced (SD) DKK1 expression (DKK1-high) achieved an ORR of 90%, compared to ORR of 56% $LPTX 2/4
DKK1-low patients comb. had strong efficacy patients w/ low PD-L1 expression (vCPS<5) w/ an ORR of 79%, compared to ORR of 67% achieved by patients w/ high PD-L1 expression (vCPS≥5. ORR data to date & currently 16 patients remaining in study likely achieves DOR & PFS. $LPTX 3/4
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(